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of breast cancer with BMs was derived assuming a steady state approach (with 
incidence equivalent to mortality of metastatic disease), and the average sur-
vival for metastatic breast cancer patients from published literature. Annual SRE 
rates from a European observational retrospective study and the treatment effect 
observed in a head-to-head clinical trial of denosumab versus zoledronic acid 
were used to estimate the total number of predicted SREs by treatment option. 
Country-specific findings from two retrospective studies were used to estimate 
the total number of hospitalisations, inpatient days and direct medical costs 
associated with the management of SREs. Results: Across all countries, the 
estimated prevalence of breast cancer patients with BMs was 87,592 patients: 
Austria, 3,253; Czech Republic, 3,509; Germany, 37,895; Greece, 4,639; Italy, 27,767; 
Spain, 7,553; and Switzerland, 2,975. When denosumab was the selected treat-
ment option, 36,324 SREs were estimated to be avoided per year compared with 
the use of zoledronic acid, which would save 24,110 hospitalisations, 536,551 
inpatient days and 206,605,754€ of direct medical costs (2014 costs in € : Austria, 
23,890,554; Czech Republic, 5,779,856; Germany, 60,659,628; Greece, 15,941,728; 
Italy, 39,998,970; Spain, 17,249,548; and Switzerland, 43,085,469). ConClusions: 
Denosumab’s clinical superiority in the prevention of SREs over zoledronic acid 
could result in significant savings in the number and duration of hospitalisa-
tions, reducing direct medical costs associated with the management of SREs in 
Europe.
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objeCtives: In the UK, PCa is the second most common male cancer resulting in 
over 10,000 deaths annually. LHRH agonists (LHRHa), a type of androgen depriva-
tion therapy, are used to help control PCa and delay progression. LHRHa injections 
are available as 1-, 3- and 6-monthly formulations. Triptorelin is the only LHRHa in 
the UK available as a 6-monthly formulation. DESERVE aimed to collect RWE about 
clinical and practical outcomes for patients starting on, or switching to, 6-monthly 
triptorelin. Methods: A customised data collection programme was designed 
including up to 2 years of data entered retrospectively by physicians from patient 
records at three UK hospitals and prospectively updated over a 5-month period. 
All patients on 6-monthly triptorelin were eligible for entry. The primary outcome 
measure was change in the number of patient–NHS interactions (patient reviews, 
PSA tests and LHRHa injections). Results: 115 patient records were entered; 
records for 88 patients had complete data and were included in the analysis. 47 
were newly diagnosed and initiated on 6-monthly triptorelin; 41 were switched 
from any 3-monthly LHRHa to 6-monthly triptorelin. For switch patients, there was 
a statistically significant reduction in the number of reviews (by 48.4%; p< 0.0001), 
injections (48.4%; p< 0.0001) and PSA tests (29.8%; p< 0.0001) in the 12 months 
following switch versus 12 months before. The total number of patient–NHS inter-
actions was significantly reduced (43.5%; p< 0.0001). At 12 months, median PSA 
was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 
ng/mL (0.35 ng/mL at switch) for switch patients. No safety issues were identi-
fied. ConClusions: Patient–NHS interactions were significantly reduced and 
PSA control was maintained with 6-monthly triptorelin vs any 3-monthly LHRHa, 
which translates into NHS savings and improvement in the overall patient experi-
ence. Use of 6-monthly triptorelin may therefore offer advantages over 3-monthly 
formulations for patients, prescribers and payors.
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objeCtives: To provide a scientific basis for the clinical use of drugs and the devel-
opment of government drug policy through pharmacoeconomic study of rituximab 
combined with conventional chemotherapy in treating patients with diffuse large 
B-cell lymphoma. Methods: From the perspective of the health care system, with 
60 years older diffuse large B-cell lymphoma patients in this study, the three-month 
cycle Markov models was established with the time limit of five years and 30 years. 
By controlling treatment, the total direct medical costs of each health status in three 
months associated with DLBCL was got through expert advice and the methods 
Price*Number. The transfer probability between the health statues was calculated 
through survival data of clinical trial; health outcomes within three months of DLBCL 
patients were obtained from literature. On this basis, the pharmacoeconomics eval-
uation was conducted of two programs of rituximab combined with conventional 
chemotherapy and conventional chemotherapy in treating DLBCL. Results: The 
basic analysis showed that: model runs for 5 years, R-CHOP group is more effec-
tive than CHOP group (2.55QALYs> 1.90QALYs), with the higher cost than CHOP 
group (612564.37yuan> 138212.22yuan), the incremental cost-effectiveness ratio 
is 735297.10yuan/QALY.Model runs for 30 years, R-CHOP group is more effec-
tive than CHOP group (4.14QALYs> 2.51QALYs), with the higher cost than CHOP 
group (887550.16yuan> 221662.73yuan), the incremental cost-effectiveness ratio 
is 407808.50yuan/QALY. According to the willingness to pay range (48857.55yuan-
146572.7yuan) which was set by China’s per capita GDP, R-CHOP program has higher 
cost and better effect, but does not have cost-effectiveness advantage in five or 
thirty years. ConClusions: Based on the research’s results and China’s current 
situation, we can say that rituximab combined with conventional chemotherapy 
for DLBCL patients compared with single conventional scheme does not have the 
cost-effectiveness advantage in 5 or 30 years.
objeCtives: Thromboembolic (TE) events are a major complication of polycythemia 
vera (PV). Little is known about economic implications of TE events in such patients. 
This study aims to assess the incremental health care resource use (HCRU) and 
costs associated with PV and post-PV TE events in a real-world patient popula-
tion. Methods: We conducted a retrospective cohort study of PV patients aged < 65 
years enrolled in employer-sponsored commercial health plans in the US. Annual 
all-cause and PV-related HCRU and costs (adjusted to 2014 US dollars) among PV 
patients were compared against non-PV comparison subjects who were propen-
sity-matched on demographics and comorbidities. For patients with a post-PV TE 
event, average 12-month costs following index TE event were assessed. Costs were 
also analyzed in a subgroup receiving hydroxyurea treatment. Results: A total 
of 12,990 PV patients (diagnosed 2000-2012) were included. HCRU was generally 
higher among PV patients versus matched comparison subjects, with largest dif-
ference observed for outpatient hospital visits (90% vs. 70% respectively, p < 0.0001). 
Mean all-cause annual total costs among PV patients were significantly greater 
than comparison subjects ($17,418 vs. $10,501, P < 0.0001). In a subset of patients 
treated with hydroxyurea (n= 774), mean PV-related annual total costs ($7,657) were 
nearly 3 times higher in contrast to costs observed among all PV patients ($2,535). 
Among PV patients experiencing TE events, mean 12-month all-cause costs were 
more than 4 times higher than among those with no TE event ($48,211 vs. $10,958, 
P < 0.0001). ConClusions: Total all-cause HCRU and costs in PV patients were 
substantially higher compared to a matched non-PV comparison group. Patients 
receiving hydroxyurea had higher costs, potentially reflective of inherently more 
severe disease in this patient subgroup. Costs were also substantially higher among 
patients experiencing post-PV TE events, highlighting the importance of treatments 
that may reduce cardiovascular complications in patients with PV.
PCN298
the CliNiCAl ANd eCoNoMiC burdeN oF SkeletAl relAted eveNtS 
iN AuStriA, CzeCh rePubliC, gerMANy, greeCe, itAly, SPAiN ANd 
SwitzerlANd: A CoMPAriSoN betweeN the uSe oF deNoSuMAb ANd 
zoledroNiC ACid iN PAtieNtS with ProStAte CANCer ANd boNe 
MetAStASeS
Cristino J1, Finek J2, Maniadakis N3, Perez Encinas M4, Ikenberg R5, Campos Tapias I6, 
Jandova P7, Zahn DP8, Moser C9, Bolognese L10, Tritaki G11, Gatta F1, Hechmati G1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Clinic of Oncology and radiotherapy (FN v PLZN), 
Plzen, Czech Republic, 3Department of Health Services Organization, National School of Public 
Health, Athens, Greece, 4Hospital Universitario Fundacion Alcorcon, Madrid, Spain, 5Amgen 
GmbH, Munich, Germany, 6Amgen SA, Barcelona, Spain, 7Amgen s.r.o, Praha, Czech Republic, 
8Amgen Switzerland AG, Zug, Switzerland, 9Amgen GmbH, Vienna, Austria, 10Amgen Srl, Milan, 
Italy, 11AMGEN Hellas Ltd, Athens, Greece
objeCtives: To estimate the total number of skeletal-related events (SREs), the 
associated hospital burden and direct medical costs when denosumab is used 
instead of zoledronic acid in patients with prostate cancer (PC) and bone metasta-
ses (BMs). Methods: A model was developed using the following data: country-
specific PC mortality data from the World Health Organization or local registries; 
the proportion of PC patients with BMs from published literature; the prevalence 
of BMs in the metastatic PC population assuming a steady state approach (with 
mortality of metastatic disease equivalent to incidence); and the average survival 
of metastatic PC patients from published literature. Both the annual SREs rates 
from a European observational study and the treatment effect of denosumab 
versus zoledronic acid reported in a head-to-head clinical trial were used to 
predict the total number of SREs by treatment. Country-specific data from two 
multi-country observational studies were used to estimate the total number of 
hospitalisations, length of inpatient stays and direct medical costs associated with 
the management of SREs. Results: Of the 67,375 patients with PC and BMs, the 
prevalence by country was: Austria, 2,447; Czech Republic, 2,707; Germany, 28,447; 
Greece, 3,888; Italy, 16,683; Spain, 9,428; and Switzerland, 2,776. If denosumab was 
the selected treatment option for all patients, an estimated 38,690 SREs per year 
could be avoided, leading to 14,599 fewer hospitalisations, a reduction of 270,007 
inpatient days, and 155,213,984€ of savings in direct medical costs per year. The 
2014 costs saved by country were: Austria, 19,919,201€ ; Czech Republic, 4,095,737€ ; 
Germany, 36,895,464€ ; Greece, 18,504,154€ ; Italy, 24,529,334€ , Spain, 18,931,728€ and 
Switzerland, 31,338,666€ . ConClusions: Denosumab can result in significant 
reductions in the number and length of inpatient stays of PC patients with BMs, 
leading to substantial savings of direct medical costs associated with the manage-
ment of SREs in each of the 7 European countries.
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objeCtives: To estimate the total number of skeletal-related events (SREs) 
prevented, related hospital burden and direct medical expenditure when deno-
sumab is used instead of zoledronic acid for SRE prevention in seven European 
countries. Methods: A model was developed combining country-specific breast 
cancer mortality data from the World Health Organization or from local regis-
tries, the proportion of metastatic breast cancer patients with bone metastases 
(BMs) at high risk of developing SREs from published literature, the prevalence 
